{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:32:53Z","timestamp":1793622773802,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.revmed.2026.07.012","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T12:34:54Z","timestamp":1787574894000},"page":"581-583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["L\u2019avacopan, une question de confiance"],"prefix":"10.1016","volume":"47","author":[{"given":"Alexandre","family":"Terr\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"Mamzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Naudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2026.07.012_bib0095","series-title":"Research C for DE and CDER proposes to withdraw approval of TAVNEOS","year":"2026"},{"key":"10.1016\/j.revmed.2026.07.012_bib0100","unstructured":"FDA avacopan full document [Internet]. Disponible sur\u00a0: https:\/\/www.fda.gov\/media\/192160\/download."},{"key":"10.1016\/j.revmed.2026.07.012_bib0105","series-title":"EMA recommends revoking marketing authorisation for Tavneos","year":"2026"},{"key":"10.1016\/j.revmed.2026.07.012_bib0110","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.07.012_bib0115","unstructured":"ChemoCentryx, Inc. | Bernstein Litowitz Berger & Grossmann LLP [Internet]. [cit\u00e9 le 26\u00a0mai 2026]. Disponible sur\u00a0: https:\/\/www.blbglaw.com\/cases-investigations\/chemocentryx-inc."},{"key":"10.1016\/j.revmed.2026.07.012_bib0120","series-title":"Tavneos","year":"2021"},{"key":"10.1016\/j.revmed.2026.07.012_bib0125","unstructured":"Base de donn\u00e9es publique des m\u00e9dicaments [Internet]. [cit\u00e9 le 26\u00a0mai 2026]. Disponible sur\u00a0: https:\/\/base-donnees-publique.medicaments.gouv.fr\/medicament\/69292539\/extrait."},{"key":"10.1016\/j.revmed.2026.07.012_bib0130","unstructured":"data.ansm.sante.fr [Internet]. [cit\u00e9 le 26\u00a0mai 2026]. Disponible sur\u00a0: https:\/\/data.ansm.sante.fr."},{"key":"10.1016\/j.revmed.2026.07.012_bib0135","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","article-title":"Why most published research findings are false?","volume":"2","author":"Ioannidis","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.revmed.2026.07.012_bib0140","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jclinepi.2013.10.019","article-title":"The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index","volume":"67","author":"Walsh","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.revmed.2026.07.012_bib0145","doi-asserted-by":"crossref","first-page":"106151","DOI":"10.1016\/j.cct.2020.106151","article-title":"Fragility of clinical trials across research fields: a synthesis of methodological reviews","volume":"97","author":"Holek","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.revmed.2026.07.012_bib0150","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.07.012_bib0155","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.07.012_bib0160","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2026.07.012_bib0165","doi-asserted-by":"crossref","first-page":"112920","DOI":"10.1016\/j.ejca.2023.05.008","article-title":"Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017\u00a0and 2021: a meta-research study","volume":"189","author":"Rossi","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2026.07.012_bib0170","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamaoncol.2019.0167","article-title":"Analysis of control arm quality in randomized clinical trials leading to anticancer drug approval by the US Food and Drug Administration","volume":"5","author":"Hilal","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.revmed.2026.07.012_bib0175","doi-asserted-by":"crossref","first-page":"e1003726","DOI":"10.1371\/journal.pmed.1003726","article-title":"An open science pathway for drug marketing authorization\u00a0\u2013\u00a0registered drug approval","volume":"18","author":"Naudet","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.revmed.2026.07.012_bib0090","unstructured":"Amgen [Internet]. [cit\u00e9 le 5\u00a0mai 2026\u00a0May 5]. AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4\u00a0BILLION IN CASH. Disponible sur\u00a0: https:\/\/www.amgen.com\/newsroom\/press-releases\/2022\/08\/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash."}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326006727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326006727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:21:52Z","timestamp":1793622112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866326006727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0248866326006727"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2026.07.012","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L\u2019avacopan, une question de confiance","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2026.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}